Moleculin Biotech Inc. (MBRX) had a rough Friday. The biopharma company's stock sank more than 63% after it priced a dilutive public offering and released updated data from its key leukemia trial. It's a classic one-two punch that left investors reeling.
First, the financing. Moleculin priced a public offering of roughly 12.38 million shares, along with warrants to buy up to 37.13 million shares, at a combined price of 75 cents per share and associated warrant. That's a steep discount to the previous closing price, and it's why the stock is now trading at $0.88, down 63.53% at the time of publication, according to market data.
The company says the proceeds will fund its ongoing clinical programs, specifically to advance Annamycin through clinical development, and to cover general working capital needs. But investors are clearly worried about dilution, and the market's reaction speaks volumes.
What the Latest MIRACLE Data Shows
Alongside the offering, Moleculin released updated blinded preliminary results from Part A of its Phase 2/3 MIRACLE trial. The trial is evaluating Annamycin in combination with cytarabine for patients with relapsed or refractory acute myeloid leukemia (AML).
The latest data, covering 62 evaluable participants, showed a blinded complete remission rate of 24% and a composite complete remission rate of 37%. Notably, about 48% of these patients had previously failed treatments based on AbbVie Inc.'s (ABBV) Venclexta (venetoclax), yet they showed response rates equivalent to the overall study group. That's an encouraging sign, especially for a hard-to-treat population.
But here's the catch: because these figures are still blinded and include control subjects, they're lower than the unblinded interim readout from June 2026. That earlier data showed composite remission rates up to 57% in the Annamycin arms, compared to 29% in the control cohort. The difference is expected, but it's worth noting that the current numbers are not apples-to-apples with the earlier, more optimistic figures.
Enrollment and Timeline
On the operational side, the trial has expanded to 74 of 90 planned subjects across 33 global clinical sites. The MIRACLE study is open to second-line leukemia patients who have received a single prior induction therapy, with recruitment ongoing in the U.S. and Europe.
The company expects to treat its 90th patient in September 2026, with full data unblinding anticipated between December 2026 and February 2027. Crucially, trial administration continues without any recorded signs of cardiotoxicity, which is a key safety metric for this type of therapy.
So, what's the takeaway? Moleculin is making progress on the clinical front, but the financing has spooked investors. The steep discount and the dilution are hard to ignore, even if the trial data shows promise. For now, the market is voting with its feet, and the stock is paying the price.
